Search
Avidity Biosciences Inc
RNAAdd to Watchlist
11.489USD
-0.421-3.53%
Close 07-24 16:00（ET）Quotes delayed by 15 min
196.53MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Avidity Biosciences Inc is 8.00, ranking 56 out of 155 in the Pharmaceuticals industry. The average price target is 72.00, with a high of 96.00 and a low of 65.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
25.000
Target Price
+103.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Avidity Biosciences Inc
RNA
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Avidity Biosciences Inc's expected revenue for the next quarter?
Avidity Biosciences Inc's expected revenue is 1.00M.
What is Avidity Biosciences Inc's price target?
Analysts forecast that Avidity Biosciences Inc's price target is USD 72.00, with the highest forecast at USD 96.00 and the lowest forecast at USD 65.00.
How have Avidity Biosciences IncRNA's recent earnings per share performed?
The market expectation was USD -0.97, while Avidity Biosciences IncRNA's earnings per share (EPS) for the previous quarter was USD -1.70. EPS for the next quarter is expected at USD -1.16.
What is the analyst rating for Avidity Biosciences Inc?
Based on the ratings of Avidity Biosciences Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.